(IVZ) - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: BMG491BT1088
Stock: Mutual Funds, ETFs, Private Funds, Managed Portfolios
Total Rating 60
Risk 75
Buy Signal 0.65
| Risk 5d forecast | |
|---|---|
| Volatility | 33.4% |
| Relative Tail Risk | -5.48% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.18 |
| Alpha | 32.74 |
| Character TTM | |
|---|---|
| Beta | 1.509 |
| Beta Downside | 1.821 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.52% |
| CAGR/Max DD | 0.56 |
EPS (Earnings per Share)
Revenue
Description: IVZ January 06, 2026
Invesco Ltd. (NYSE:IVZ) is a global investment manager that serves a broad client base-including retail, institutional, high-net-worth, public entities, and sovereign wealth funds-through a suite of equity, fixed-income, multi-asset, and alternative strategies. The firm operates both mutual funds and ETFs, and it also manages private funds, deploying capital across public equities, bonds, commodities, and currencies, typically investing $5-$15 million per company.
As of the end of 2023, Invesco reported approximately $1.5 trillion in assets under management (AUM) and generated $6.4 billion in revenue, reflecting a 31 % operating margin. The asset-management sector is currently driven by fee compression from the shift toward low-cost passive products and heightened demand for ESG-aligned investments, which together influence net inflows and profit margins for firms like Invesco.
For a deeper quantitative assessment of Invesco’s valuation metrics, the ValueRay platform offers a concise dashboard you may find useful.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: -281.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 1.41 > 1.0 |
| NWC/Revenue: -35.42% < 20% (prev 29.32%; Δ -64.74% < -1%) |
| CFO/TA 0.06 > 3% & CFO 1.53b > Net Income -281.7m |
| Net Debt (9.76b) to EBITDA (1.38b): 7.09 < 3 |
| Current Ratio: 0.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (453.8m) vs 12m ago -0.07% < -2% |
| Gross Margin: 43.18% > 18% (prev 0.33%; Δ 4284 % > 0.5%) |
| Asset Turnover: 23.57% > 50% (prev 22.46%; Δ 1.11% > 0%) |
| Interest Coverage Ratio: -6.63 > 6 (EBITDA TTM 1.38b / Interest Expense TTM 82.5m) |
Altman Z'' 1.09
| A: -0.08 (Total Current Assets 1.04b - Total Current Liabilities 3.30b) / Total Assets 27.09b |
| B: 0.26 (Retained Earnings 7.17b / Total Assets 27.09b) |
| C: -0.02 (EBIT TTM -546.7m / Avg Total Assets 27.05b) |
| D: 0.87 (Book Value of Equity 12.23b / Total Liabilities 14.09b) |
| Altman-Z'' Score: 1.09 = BB |
Beneish M
| DSRI: none (Receivables none/1.11b, Revenue 6.38b/6.07b) |
| GMI: 0.77 (GM 43.18% / 33.41%) |
| AQI: none (AQ_t none / AQ_t-1 none) |
| SGI: 1.05 (Revenue 6.38b / 6.07b) |
| TATA: -0.07 (NI -281.7m - CFO 1.53b) / TA 27.09b) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of IVZ shares?
As of February 22, 2026, the stock is trading at USD 26.47 with a total of 4,738,755 shares traded.
Over the past week, the price has changed by -0.19%, over one month by -4.39%, over three months by +17.55% and over the past year by +54.28%.
Over the past week, the price has changed by -0.19%, over one month by -4.39%, over three months by +17.55% and over the past year by +54.28%.
Is IVZ a buy, sell or hold?
has received a consensus analysts rating of 3.07.
Therefor, it is recommend to hold IVZ.
- StrongBuy: 1
- Buy: 1
- Hold: 11
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the IVZ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 30.1 | 13.9% |
| Analysts Target Price | 30.1 | 13.9% |
IVZ Fundamental Data Overview February 21, 2026
P/E Forward = 10.0806
P/S = 1.8398
P/B = 0.9627
P/EG = 0.4184
Revenue TTM = 6.38b USD
EBIT TTM = -546.7m USD
EBITDA TTM = 1.38b USD
Long Term Debt = 10.79b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 10.79b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.76b USD (from netDebt column, last quarter)
Enterprise Value = 21.49b USD (11.73b + Debt 10.79b - CCE 1.04b)
Interest Coverage Ratio = -6.63 (Ebit TTM -546.7m / Interest Expense TTM 82.5m)
EV/FCF = 14.27x (Enterprise Value 21.49b / FCF TTM 1.51b)
FCF Yield = 7.01% (FCF TTM 1.51b / Enterprise Value 21.49b)
FCF Margin = 23.61% (FCF TTM 1.51b / Revenue TTM 6.38b)
Net Margin = -4.42% (Net Income TTM -281.7m / Revenue TTM 6.38b)
Gross Margin = 43.18% ((Revenue TTM 6.38b - Cost of Revenue TTM 3.62b) / Revenue TTM)
Gross Margin QoQ = 66.96% (prev 34.17%)
Tobins Q-Ratio = 0.79 (Enterprise Value 21.49b / Total Assets 27.09b)
Interest Expense / Debt = 0.21% (Interest Expense 23.0m / Debt 10.79b)
Taxrate = 21.0% (US default 21%)
NOPAT = -431.9m (EBIT -546.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.31 (Total Current Assets 1.04b / Total Current Liabilities 3.30b)
Debt / Equity = 0.88 (Debt 10.79b / totalStockholderEquity, last quarter 12.23b)
Debt / EBITDA = 7.09 (Net Debt 9.76b / EBITDA 1.38b)
Debt / FCF = 6.48 (Net Debt 9.76b / FCF TTM 1.51b)
Total Stockholder Equity = 13.70b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.04% (Net Income -281.7m / Total Assets 27.09b)
RoE = -2.06% (Net Income TTM -281.7m / Total Stockholder Equity 13.70b)
RoCE = -2.23% (EBIT -546.7m / Capital Employed (Equity 13.70b + L.T.Debt 10.79b))
RoIC = -3.50% (negative operating profit) (NOPAT -431.9m / Invested Capital 12.34b)
WACC = 6.06% (E(11.73b)/V(22.53b) * Re(11.48%) + D(10.79b)/V(22.53b) * Rd(0.21%) * (1-Tc(0.21)))
Discount Rate = 11.48% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.08%
[DCF Debug] Terminal Value 87.86% ; FCFF base≈1.35b ; Y1≈1.67b ; Y5≈2.84b
Fair Price DCF = 154.6 (EV 78.42b - Net Debt 9.76b = Equity 68.66b / Shares 444.0m; r=6.06% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 42.74 | EPS CAGR: 2.75% | SUE: 0.73 | # QB: 0
Revenue Correlation: 46.64 | Revenue CAGR: 1.01% | SUE: 3.37 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.59 | Chg30d=+0.021 | Revisions Net=+2 | Analysts=10
EPS current Year (2026-12-31): EPS=2.68 | Chg30d=+0.104 | Revisions Net=+4 | Growth EPS=+32.2% | Growth Revenue=+13.7%
EPS next Year (2027-12-31): EPS=3.05 | Chg30d=+0.081 | Revisions Net=+5 | Growth EPS=+13.5% | Growth Revenue=+6.2%
P/S = 1.8398
P/B = 0.9627
P/EG = 0.4184
Revenue TTM = 6.38b USD
EBIT TTM = -546.7m USD
EBITDA TTM = 1.38b USD
Long Term Debt = 10.79b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 10.79b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.76b USD (from netDebt column, last quarter)
Enterprise Value = 21.49b USD (11.73b + Debt 10.79b - CCE 1.04b)
Interest Coverage Ratio = -6.63 (Ebit TTM -546.7m / Interest Expense TTM 82.5m)
EV/FCF = 14.27x (Enterprise Value 21.49b / FCF TTM 1.51b)
FCF Yield = 7.01% (FCF TTM 1.51b / Enterprise Value 21.49b)
FCF Margin = 23.61% (FCF TTM 1.51b / Revenue TTM 6.38b)
Net Margin = -4.42% (Net Income TTM -281.7m / Revenue TTM 6.38b)
Gross Margin = 43.18% ((Revenue TTM 6.38b - Cost of Revenue TTM 3.62b) / Revenue TTM)
Gross Margin QoQ = 66.96% (prev 34.17%)
Tobins Q-Ratio = 0.79 (Enterprise Value 21.49b / Total Assets 27.09b)
Interest Expense / Debt = 0.21% (Interest Expense 23.0m / Debt 10.79b)
Taxrate = 21.0% (US default 21%)
NOPAT = -431.9m (EBIT -546.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.31 (Total Current Assets 1.04b / Total Current Liabilities 3.30b)
Debt / Equity = 0.88 (Debt 10.79b / totalStockholderEquity, last quarter 12.23b)
Debt / EBITDA = 7.09 (Net Debt 9.76b / EBITDA 1.38b)
Debt / FCF = 6.48 (Net Debt 9.76b / FCF TTM 1.51b)
Total Stockholder Equity = 13.70b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.04% (Net Income -281.7m / Total Assets 27.09b)
RoE = -2.06% (Net Income TTM -281.7m / Total Stockholder Equity 13.70b)
RoCE = -2.23% (EBIT -546.7m / Capital Employed (Equity 13.70b + L.T.Debt 10.79b))
RoIC = -3.50% (negative operating profit) (NOPAT -431.9m / Invested Capital 12.34b)
WACC = 6.06% (E(11.73b)/V(22.53b) * Re(11.48%) + D(10.79b)/V(22.53b) * Rd(0.21%) * (1-Tc(0.21)))
Discount Rate = 11.48% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.08%
[DCF Debug] Terminal Value 87.86% ; FCFF base≈1.35b ; Y1≈1.67b ; Y5≈2.84b
Fair Price DCF = 154.6 (EV 78.42b - Net Debt 9.76b = Equity 68.66b / Shares 444.0m; r=6.06% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 42.74 | EPS CAGR: 2.75% | SUE: 0.73 | # QB: 0
Revenue Correlation: 46.64 | Revenue CAGR: 1.01% | SUE: 3.37 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.59 | Chg30d=+0.021 | Revisions Net=+2 | Analysts=10
EPS current Year (2026-12-31): EPS=2.68 | Chg30d=+0.104 | Revisions Net=+4 | Growth EPS=+32.2% | Growth Revenue=+13.7%
EPS next Year (2027-12-31): EPS=3.05 | Chg30d=+0.081 | Revisions Net=+5 | Growth EPS=+13.5% | Growth Revenue=+6.2%